By Admin at 22 Jul 2016
Researchers at Oxford and Nottingham Universities have developed a new drug that may help slow down the growth of triple negative breast cancer — considered the most aggressive and hardest-to-treat form of breast cancer.
58
Current Gateway-funded clinical trials
150+
Clinical trials funded at leading institutions worldwide
$16.56
Funds one patient for one day at a Gateway-funded clinical trial
